The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis
نویسندگان
چکیده
منابع مشابه
Biochemical markers of disease progression in sporadic amyotrophic lateral sclerosis
The main aim of our study was monitoring of indices of anti-oxidant activity in SALS patients. 28 patients (13 males, 15 females; mean age 58.5±12, 3 years; mean duration 25.9±5, 5 months) were monitored during 6 months. Every month the patients were examined neurologically, ALS functional rating scale, the pulmonary dysfunction by measurement of FVC, evaluated functional disability. The indice...
متن کاملPredicting disease progression in amyotrophic lateral sclerosis
OBJECTIVE It is essential to develop predictive algorithms for Amyotrophic Lateral Sclerosis (ALS) disease progression to allow for efficient clinical trials and patient care. The best existing predictive models rely on several months of baseline data and have only been validated in clinical trial research datasets. We asked whether a model developed using clinical research patient data could b...
متن کاملQuantifying Disease Progression in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of disease progression, with inherent clinical heterogeneity making disease quantitation difficult. Recent advances in understanding pathogenic mechanisms linked to the development of ALS impose an increasing need to develop strategies to predict and more objectively measure disease progression. This revie...
متن کاملAmyotrophic Lateral Sclerosis in a Patient with Behçet’s Disease
Behçet’s disease is a multisystem vasculitis. Its neurological involvement mostly includes parenchymal and non-parenchymal central nervous system manifestations. Peripheral nervous system presentations are rare. A 32-yr-old male patient who fulfilled the international study group criteria for Behçet’s disease, referred to our center with walking difficulty and repeated falling downs. Neurologi...
متن کاملLithium delays progression of amyotrophic lateral sclerosis.
ALS is a devastating neurodegenerative disorder with no effective treatment. In the present study, we found that daily doses of lithium, leading to plasma levels ranging from 0.4 to 0.8 mEq/liter, delay disease progression in human patients affected by ALS. None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
سال: 2020
ISSN: 2167-8421,2167-9223
DOI: 10.1080/21678421.2020.1773501